GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Is Cheaper Stem Cell Therapy Better Value?

Cheaper stem cell therapy can be better value, but a lower quote alone cannot establish that. It may offer a genuine saving when the treatment, evidence, safety arrangements, and follow-up are comparable and the total cost is lower. A higher fee does not prove better results, either. If benefit remains uncertain, the first question is whether to have the treatment at all—not which clinic offers the biggest discount.

Two Japanese knee osteoarthritis plans illustrate the problem. They list about ¥1,000,000 and ¥1,400,000 for injections using the patient’s own fat-derived mesenchymal stromal/stem cells (MSCs). The nominal dose is 100 million cells, but the price units and tax wording differ21. Neither document establishes that one option delivers better outcomes than the other.

Is Cheaper Stem Cell Therapy Better Value?

These are private-pay services, not evidence that the treatments are approved products or that either is cost-effective. Clinical evidence must be considered separately: a 2025 Cochrane review found that stem cell injections may slightly improve knee pain and function compared with placebo, with low-certainty evidenceCD013342_what are benefits and risks stem cell injections knee osteoarthritis. The examples below concern knee osteoarthritis, not cancer treatment, other diseases, or anti-aging.

What the Cheaper Price Covers

Item Plan A: NeoPolis Clinic Ginza Plan B: Hachiman Clinic
Condition Knee osteoarthritis Knee osteoarthritis
Cell type Autologous fat-derived MSCs Autologous fat-derived MSCs
Dose priced 100 million cells per knee 100 million cells per administration
Route Joint injection Joint injection
Listed price About ¥1,000,000, culture and storage included; tax unstated ¥1,400,000, culture and storage included, tax included
Follow-up stated Six-month assessment, including blood tests, general condition, and pain Six-month assessment by visit or telephone where possible, including pain and adverse events

The difference between the listed figures is about ¥400,000, or 40% of the lower figure. That is not a tax-adjusted, like-for-like saving: Plan A prices one knee, Plan B prices an administration, and Plan A does not state its tax treatment. These are archived plan examples, not a national price list or current quotations21.

What the Document Comparison Reveals

Comparing the two 13-page Japanese documents means going beyond the headline price. In section 8, Plan A also lists ¥100,000 for another fat collection if an insufficient cell yield requires re-collection. Both documents warn that some fees cannot be refunded after fat collection21. Ask for a written explanation of what you would owe if cell preparation fails or treatment stops. This is a comparison of consent documents, not a clinic inspection or patient-outcome assessment. The archived versions were rechecked on 27 October 2026; request the current consent form and quotation before paying.

Same Number, Different Product

A cell-count label alone does not tell you whether two preparations are equivalent. Stromal vascular fraction (SVF) is a heterogeneous pool of cells from fat; isolated mesenchymal stromal/stem cells are a different preparation. They should not be treated as interchangeable treatments at different prices31544555.

For each quote, ask whether the cells are your own or from a donor, whether they are cultured, how the dose is measured, and what proportion is viable at release. Request the cell-processing facility details and the identity, sterility, and other release-test criteria. Matching a nominal count is not enough to establish matching quality or benefit.

Filing Is Not Efficacy Approval

For services covered by Japan’s Act on the Safety of Regenerative Medicine, providers generally need committee review and a filed provision plan. The framework also includes reporting obligations and record keepingPlan. These are relevant safety and oversight checks, but a filing is not regulatory approval of clinical efficacy.

Regenerative medical product approval follows the separate Pharmaceuticals and Medical Devices Act. An approved product has a defined indication; that approval does not extend to every treatment using cells with a similar name000280868.pdf. Ask whether the exact intervention is an approved product used for its approved indication, a clinical study, or a private-pay service under a provision plan. A study registration records a study, not proof that it works.

Plan A describes the treatment, in translation, as a new method at the research stage for which an accurate track record of safety and treatment effects has not yet been reported2. This is the provider’s consent wording, not an MHLW finding that the treatment is effective.

Benefit for the Money

The 2025 Cochrane review included 25 randomized trials with 1,341 participants; eight trials with 459 participants compared knee injections with placebo. The review’s search was current to 15 September 2023, so its publication year should not be mistaken for the date of the newest included evidenceCD013342_what are benefits and risks stem cell injections knee osteoarthritis.

At six months, pain was estimated at 3.3 out of 10 with stem cell injections versus 4.5 with placebo: a 1.2-point difference. Function scores were 32.1 versus 46.3 out of 100, a 14.2-point difference, with lower scores indicating better function. Pain estimates used seven studies with 445 participants; function estimates used seven with 432. Certainty was low because preparations and doses differed and publication bias was suspected. The pain difference’s 95% confidence interval ranged from no improvement to 2.5 points betterCD013342_what are benefits and risks stem cell injections knee osteoarthritis.

No included trial assessed radiographic disease progression. Evidence about serious harms was very uncertain. These pooled results do not establish cartilage regrowth, a reliable response rate for either Japanese plan, or which preparation offers the best valueCD013342_what are benefits and risks stem cell injections knee osteoarthritis. Ask for published results using the clinic’s actual protocol in patients with a similar diagnosis and severity—not testimonials or results from a different disease.

Cheap Quote, Full Cost

Request a written, itemized quote covering the same number of knees, injections, and visits. For budgeting, compare a 12-month total: consultation, tests, fat collection, processing, storage, administration, follow-up, and any planned repeat treatment. Add travel and accommodation and time away from work. Twelve months is a comparison window, not a claim that benefits last that long.

Keep contingent charges separate: re-collection, failed culture, cancellation, unplanned visits, and complication care. Ask who pays and whether there is a limit. A written base price cannot guarantee a fixed total if complications occur.

A lower price can be a real saving if it buys comparable care. But neither plan provides the comparative outcome data needed to calculate reliable cost-effectiveness. Even a clinic’s reported improvement rate needs a patient denominator, a definition of improvement, follow-up duration, and a suitable comparison group before it can support a value claim.

When Cheap Costs More

Treat these as reasons to pause and ask for documentation, not proof that a clinic is unsafe:

  • Price quoted per injection rather than per course.
  • Cell count advertised without viability, identity, and sterility testing.
  • Processing site and quality oversight left unstated.
  • No defined follow-up or route to in-person assessment when needed; important charges left outside the quote.
  • Result guaranteed or time pressure applied, with no plan for complications after returning home.

Complication arrangements matter regardless of price. In 2018, CDC reported 12 patients hospitalized in three U.S. states after receiving contaminated, unapproved cord blood-derived products; none diedMm6750a5.htm. A separate report published in 2024 described three patients who developed Mycobacterium abscessus infections after embryonic stem cell injections in Mexico in 2022; treatment was ongoing as of 28 March 2024Mm7318a3.htm. These involved different products and settings from the Japanese knee plans. They demonstrate possible serious harm, not its frequency or a relationship between low prices and infection.

Value Checklist

Use this table to test whether a cheaper quote is genuinely comparable before treating its price as better value.

Compare Why it matters Ask for
Diagnosis and stage Evidence must fit the condition and patient Diagnosis, severity, eligibility and contraindications, and alternatives
Cell type and source Autologous fat, marrow, donor cells, SVF, cultured MSCs differ Cell name, source, cultured or same-day
Dose and viability Count does not show live cells or potency Cells per administration, viability at release, potency testing
Route and doses A price per injection may not cover the proposed course Route, sites, administrations, interval
Evidence A controlled trial is more informative than a testimonial Protocol-matched results, comparison group, and follow-up
Regulatory status Safety filing is not efficacy approval Approved product, trial, or private-pay care
12-month total Headline may exclude tests, storage, follow-up, travel Itemized inclusions and exclusions
Follow-up 6-month pain check differs from 12-month outcome Who follows up, how, how long, emergency cover
Failure rules Culture can fail or miss dose Refunds, recharges, cancellation terms
Travel and time Separate collection and treatment visits can add costs Actual visit schedule, trip costs, and time off work

Comparing two knee quotes with different cell counts and follow-up?

Send the itemized prices and follow-up terms for a like-for-like check before you pay.

Request an itemized review

Bottom Line

Do not pay more just because a treatment is expensive, or choose it just because it is discounted. The roughly ¥400,000 difference in these two listed prices is not proof of a clinical advantage or a like-for-like saving21. First discuss whether the treatment is justified compared with standard care with a clinician who is not selling the procedure. Then compare documented care and full costs. If the evidence does not justify either option, declining both remains a valid choice.

This article is general information, not medical advice or a clinic recommendation. Outcomes vary by condition, patient, product, and provider. No treatment is guaranteed.